© Copyright 2017 The Journal of Rheumatology. All rights reserved. Objective. The antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are multiorgan diseases. Patients with AAV report impairment in their health-related quality of life (HRQOL) and have different priorities regarding disease assessment compared with physicians. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group previously received endorsement for a core set of domains in AAV. Two approaches to measure patient-reported outcomes (PRO) were presented at OMERACT 2016. Methods. A novel 5-step tool was used to facilitate assessment of the instruments by delegates: the OMERACT Filter 2.0 Instrument Selection Algorithm, with a red-amber-green checkl...
ABSTRACTObjective: The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) a...
There has been a marked increase in the past 15 years in the number and quality of clinical trials i...
Copyright © 2017. All rights reserved. Objective. Among the challenges in conducting clinical trials...
© Copyright 2017 The Journal of Rheumatology. All rights reserved. Objective. The antineutrophil cyt...
Objective. The antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are multiorgan dise...
Objective. The antineutrophil cytoplasmic antibody–associated vasculitides (AAV) are multiorgan dise...
The Journal of Rheumatology Copyright © 2015. All rights reserved. Objective. Antineutrophil cytopla...
Objective. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of link...
To access publisher's full text version of this article click on the hyperlink belowObjective: The O...
© 2018 Article author(s). Objectives To finalise and validate a disease-specific patient-reported ou...
OBJECTIVE:The OMERACT Vasculitis Working Group seeks to develop validated outcome measures for use i...
Objective: The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are multisy...
OBJECTIVE: The Patient Reported Outcome Measurement Information System (PROMIS) is a collection of i...
ABSTRACTObjective: The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) a...
There has been a marked increase in the past 15 years in the number and quality of clinical trials i...
Copyright © 2017. All rights reserved. Objective. Among the challenges in conducting clinical trials...
© Copyright 2017 The Journal of Rheumatology. All rights reserved. Objective. The antineutrophil cyt...
Objective. The antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are multiorgan dise...
Objective. The antineutrophil cytoplasmic antibody–associated vasculitides (AAV) are multiorgan dise...
The Journal of Rheumatology Copyright © 2015. All rights reserved. Objective. Antineutrophil cytopla...
Objective. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of link...
To access publisher's full text version of this article click on the hyperlink belowObjective: The O...
© 2018 Article author(s). Objectives To finalise and validate a disease-specific patient-reported ou...
OBJECTIVE:The OMERACT Vasculitis Working Group seeks to develop validated outcome measures for use i...
Objective: The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are multisy...
OBJECTIVE: The Patient Reported Outcome Measurement Information System (PROMIS) is a collection of i...
ABSTRACTObjective: The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) a...
There has been a marked increase in the past 15 years in the number and quality of clinical trials i...
Copyright © 2017. All rights reserved. Objective. Among the challenges in conducting clinical trials...